The Endocannabinoid System, Explained

A signaling system worth understanding

The endocannabinoid system, or ECS, is a network of molecules, receptors, and enzymes that helps cells communicate. Researchers study its involvement in processes including appetite, memory, stress responses, immune signaling, and the body’s daily rhythms.

Its name connects it to cannabis, but the system exists whether or not someone uses hemp products. Your body makes its own cannabinoid-signaling molecules. Plant-derived cannabinoids, including cannabidiol (CBD), are separate compounds that researchers are studying for their interactions with this biology.

Understanding that distinction is a useful starting point. The ECS is not a wellness trend or a switch that a product simply turns on. It is a complex, context-dependent signaling network—and the science is still developing.

What is the endocannabinoid system?

The ECS is usually described through three core components:

• Endocannabinoids: signaling molecules produced within the body.
• Cannabinoid receptors: proteins that respond to particular chemical signals.
• Enzymes: proteins involved in making and breaking down endocannabinoids.

These components operate together, rather than as isolated parts. A cell produces a signal, that signal interacts with a receptor, and enzymes help determine how long the message remains active.

In their review An Introduction to the Endogenous Cannabinoid System, published in Biological Psychiatry in 2016, researchers Hui-Chen Lu and Ken Mackie describe this system and its role in regulating communication between cells.

The ECS is often discussed in relation to homeostasis: the ongoing adjustments that keep internal conditions within workable ranges. But “balance” is shorthand, not a measurable promise. Different tissues need different responses, and greater cannabinoid signaling is not automatically better.

### Why the name sounds like cannabis

Scientists identified cannabinoid receptors while investigating how compounds in cannabis interact with the body. They subsequently identified molecules made by the body that activate those receptors.

The prefix endo- means “within.” An endocannabinoid comes from within the body; a phytocannabinoid comes from a plant.

The discovery story explains the terminology. It does not mean the body requires cannabis or hemp to keep this system functioning.

The body’s own cannabinoid messengers

Two of the best-characterized endocannabinoids are anandamide, also called AEA, and 2-arachidonoylglycerol, usually shortened to 2-AG.

Both are lipid-derived molecules, meaning their chemistry is connected to fats and the components of cell membranes. They are often produced in response to cellular activity rather than stored in advance in the same way as many conventional neurotransmitters.

### Anandamide and 2-AG

Anandamide was identified in research published in Science in 1992. Its name is sometimes used to imply a simple connection with happiness, but that framing oversimplifies its biology. Anandamide participates in signaling whose consequences depend on location, receptor activity, and other conditions.

Researchers identified 2-AG as an endogenous cannabinoid messenger in the 1990s as well. Although anandamide and 2-AG can act through cannabinoid receptors, they are not interchangeable. Their production, breakdown, and signaling roles differ.

That distinction matters when reading claims about “increasing endocannabinoids.” There is no single endocannabinoid level that explains overall wellness.

### How the messages end

Signaling molecules need an off-ramp.

The enzyme fatty acid amide hydrolase, or FAAH, is important in breaking down anandamide. Monoacylglycerol lipase, or MAGL, is a major enzyme involved in breaking down 2-AG.

Other enzymes also contribute. Together, these pathways help make endocannabinoid signaling local and responsive rather than continuously active.

CB1 and CB2: the main cannabinoid receptors

Receptors are proteins that translate a chemical interaction into activity inside a cell. The two best-characterized cannabinoid receptors are CB1 and CB2.

They belong to a large family called G protein-coupled receptors, which participate in many kinds of biological communication.

### CB1: prominent in the nervous system

CB1 receptors are abundant in the brain and also occur elsewhere in the body. In the nervous system, they can influence how much neurotransmitter a neuron releases.

One distinctive feature is retrograde signaling. In a common pattern of communication, a sending neuron releases a neurotransmitter toward a receiving neuron. Endocannabinoids can travel in the opposite direction, carrying feedback from the receiving cell back toward the sender.

This feedback can adjust subsequent neurotransmitter release. Researchers István Katona and Tamás Freund discuss these functions in their 2012 review in Annual Review of Neuroscience.

This is more precise than saying the ECS simply “calms the brain.” Its effects depend on which cells and circuits are involved.

### CB2: important in immune signaling

CB2 receptors are strongly associated with immune cells, although their distribution is not limited to the immune system.

Researchers are studying how CB2 signaling participates in immune-cell activity and responses to changing tissue conditions. These are complex biological questions—not evidence that a consumer hemp product produces a particular health outcome.

The familiar shorthand “CB1 in the brain, CB2 in the body” is therefore incomplete. Both receptors have distributions and functions that resist such a clean division.

Where CBD fits—and where it does not

CBD is a plant-derived cannabinoid. It is not an endocannabinoid, and it does not simply replace anandamide or 2-AG.

It also behaves differently from tetrahydrocannabinol, or THC. THC can activate cannabinoid receptors, including CB1, which is central to its intoxicating effects. CBD does not activate CB1 and CB2 in the same straightforward way.

Researchers are studying CBD’s interactions with multiple molecular targets, including targets outside the classical ECS. Its activity may depend on concentration, biological setting, and the experimental method used.

Vincenzo Di Marzo and Fabiana Piscitelli’s review in Neurotherapeutics discusses how plant cannabinoids may influence endocannabinoid-related biology. The broader lesson is that cannabinoid pharmacology extends beyond a simple lock-and-key diagram.

### Mechanisms are not product outcomes

A finding in isolated cells can suggest a mechanism. An animal study can help researchers investigate a biological pathway. Neither, by itself, establishes what a retail product will do in a person’s daily routine.

Human research also needs context:

• Which formulation and amount were studied?
• Who participated, and for how long?
• What outcomes were measured?
• Were the results replicated?

Divine Earth’s products are broad-spectrum, with 0.0% THC. That describes their cannabinoid profile; it does not establish how an individual will respond or demonstrate a particular health benefit.

What “supporting your ECS” really means

The phrase appears frequently in wellness marketing, but it has no single, standardized meaning.

Researchers are studying how factors such as physical activity, diet, and stress relate to endocannabinoid signaling. Early research suggests these relationships are dynamic and may differ according to the tissue, timing, and individual being studied.

That does not justify promises to “reset,” “optimize,” or “repair” the ECS. Nor does feeling a certain way reveal whether someone has too much or too little endocannabinoid activity.

There is no generally accepted consumer test that translates ECS measurements into a personalized hemp routine. Proposed explanations involving endocannabinoid deficiency remain research questions, not conclusions people should apply to themselves from a symptom checklist.

Reading the science with perspective

A useful ECS article should distinguish established biology from emerging hypotheses and commercial interpretation.

Receptors and endogenous signaling molecules are well established. The idea that a particular supplement reliably creates whole-body “balance” is a much broader claim requiring its own evidence.

Safety deserves the same care. The U.S. Food and Drug Administration notes that CBD can interact with medications and carries potential risks, including liver injury in some circumstances. “Non-intoxicating” does not mean risk-free.

If you are considering CBD, particularly alongside medication, discuss it with a qualified healthcare professional. Product testing can help document composition and screen for contaminants, but it cannot establish personal suitability or guarantee an outcome.

The takeaway

The endocannabinoid system is the body’s own communication network, built around endogenous messengers, receptors, and enzymes. It works without hemp, and its activity is more complex than a simple balance switch.

CBD research is one part of that larger scientific story. Understanding the distinction between a biological mechanism and a demonstrated human outcome makes it easier to approach hemp wellness with curiosity, perspective, and realistic expectations.